Navigation Links
LX4211 Achieves Positive Results in Type 2 Diabetes Patients with Renal Impairment
Date:10/1/2013

hief medical officer.  "The post-prandial glucose reductions and GLP-1 elevations observed in this study population support the rationale for demonstrating effective HbA1c reduction in a larger, longer-term Phase 3 trial, and provide further support for the clinical differentiation of LX4211 as a first-in-class dual SGLT1 and SGLT2 inhibitor." 

In this multicenter study, 30 patients with poorly controlled type 2 diabetes and moderate to severe renal impairment were randomized to either placebo or a 400 mg dose of investigational drug LX4211 taken orally once per day before breakfast. Patients' post-prandial glucose was measured after a standardized meal both at baseline before treatment and after one week of therapy. In addition to achieving the primary efficacy objective of post-prandial glucose reduction, there were no serious adverse events observed in the study and no discontinuations of LX4211 due to adverse events. Lexicon plans to present full results of the study at scientific congresses in 2014.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX4211, characterizations of the
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
2. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
3. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
4. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
5. LX4211 Phase 2b Results Presented At American Heart Association Annual Conference
6. Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
7. Lexicon Presents Data at the American Diabetes Association Meeting On Blood Pressure Reduction and Weight Loss In Clinical Trial of LX4211
8. Greenville Hospital System Achieves Dramatic Improvement in Hand Hygiene Compliance Rates Using New Technology from DebMed®
9. Acuo Technologies Grows European Business and Achieves Successful Connectathon Results in Bern, Switzerland
10. CMC Biologics Achieves Successful Pre-Approval European GMP Inspection by MHRA for Commercial Manufacturing
11. QIAGEN Achieves Personalized Healthcare Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015  Mail-service and specialty pharmacies ... employers and government health plans $23.3 billion over ... the Pharmaceutical Care Management Association (PCMA). ... one of the easiest ways to reduce health ... Merritt . "Policymakers should resist efforts to restrict ...
(Date:2/26/2015)... Feb. 26, 2015 Every year many millions ... fight heart disease.  Nevertheless, year after year doctors and ... as the first test to determine the status of ... pain or not, even though that technology is over ... fact that doctors know, (while most patients do not ...
(Date:2/26/2015)... DUBLIN , Feb. 26, 2015 Research and ... addition of the "Radiation Therapy Equipment - Global ... This report analyzes the worldwide markets for ... Product Segments: Linear Accelerator, Treatment Planning Systems, and Radiation ... the US, Canada , ...
Breaking Medicine Technology:PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Texas Employers, Consumers and Public Programs by $23.3 Billion 2National Heart Health Month In February 2Radiation Therapy Equipment - Global Strategic Business Report 2015-2020: Linear Accelerator, Treatment Planning Systems, and Radiation Therapy Simulator 2
... 2011 Reportlinker.com announces that a new market research report ... Products http://www.reportlinker.com/p060973/Cosmetic-Surgery-Products.html ... Demand for products used in cosmetic surgery is forecast ... 2014, when 16.1 million cosmetic procedures are expected to be ...
... 2011 Medco Health Solutions, Inc. (NYSE: MHS ... to present at the following healthcare conferences: (Logo: ... CEOs Unscripted conference taking place in New York at the ... 8:45 a.m. ET; The 29th Annual JPMorgan ...
Cached Medicine Technology:Reportlinker Adds Cosmetic Surgery Products 2Reportlinker Adds Cosmetic Surgery Products 3Medco CEO to Present at Upcoming Healthcare Conferences 2
(Date:2/27/2015)... Sunnyvale, CA (PRWEB) February 27, 2015 ... showcase ClinCapture, its validated Electronic Data Capture (EDC) at ... Francisco, California on March 2nd and March 3rd at ... a self-service platform and DIY CRF and edit-check builder ... Checks in a matter of days, without any programming ...
(Date:2/27/2015)... 2015 Altec Products, Inc., announced today ... ERP Document Management Partner of the Year. ADSS Global ... and other complimentary solutions for their customers across the ... many years to provide clients with paperless solutions that ... “We are thrilled to recognize ADSS Global for their ...
(Date:2/27/2015)... In honor of American Heart Month in February, ... office, is offering tips on how to improve heart health. , ... doesn't mean people have to accept it as their fate. Although ... such as family history, sex or age — there are some ... has six helpful tips to improve heart health and prevent heart ...
(Date:2/27/2015)... 2015 Undocumented farmworkers are half ... use Medicaid, the federal health insurance program available ... new study from UC Davis Health System. The ... farmworker use of Medicaid, which provides coverage for ... status, was having children. , “Undocumented agricultural ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 The federal ... ) that allege use of the statin medication can ... has issued a new order pertaining discovery in the ... Bernstein Liebhard LLP comments. The Order, which was issued ... on February 25th, directs the parties to schedule certain ...
Breaking Medicine News(10 mins):Health News:Clinovo to Demo Its Self-Service, Cloud-Based EDC Solution at CALBIO2015 on March 2nd and 3rd, 2015 2Health News:Altec Announces 2014 Sage ERP Document Management Partner of the Year Award Recipient 2Health News:Center for Primary Care Celebrates American Heart Month 2Health News:Center for Primary Care Celebrates American Heart Month 3Health News:Center for Primary Care Celebrates American Heart Month 4Health News:UC Davis Study Finds Undocumented Farmworkers Use Medicaid Half as Often as Documented Farmworkers 2Health News:UC Davis Study Finds Undocumented Farmworkers Use Medicaid Half as Often as Documented Farmworkers 3Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 2Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 3
... While the visual regions of the brain have been ... uncharted territory. Now, researchers at the Hebrew University of ... a key auditory process perceiving sound space, the ... concentrating on those sounds. , The findings settle ...
... MEDIA, Pa., Sept. 20 Synova Healthcare Group,Inc. (OTC ... sale,of approximately $3.3 million in aggregate notional principal amount ... September 19, 2012,and related common stock purchase warrants. This ... private placement of notes and warrants in the,aggregate notional ...
... Philadelphia, PA, September 20, 2007 Pedophilia, the sexual ... health concern and it does not respond well to ... not well understood. A new study being published ... the first of its kind to use functional brain ...
... Calif., Sept. 20 Cardiva Medical, Inc.,a privately ... Chairman and CEO, will present at the UBS ... in New York City. Notably, the,company will be ... the,Boomerang Catalyst II System, which recently received a ...
... 19, 2007 -- A single dose of Otsukas ... resulted in favorable changes in hemodynamics associated with ... with advanced heart failure (ADHF) who participated in ... HemodynamIc Parameters in Subjects with HEart failure (ECLIPSE), ...
... Speaker Nancy Pelosi,issued the following statement today on ... a vote of 405 to 7:, "Today,s sweeping, ... all Americans., "Essential to the safety net of ... that the prescription drugs they buy are safe. These ...
Cached Medicine News:Health News:Sensitivity of brain center for 'sound space' defined 2Health News:Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants 2Health News:Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants 3Health News:Pedophilia patients are found to have deficits in brain activation 2Health News:Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM) 2Health News:Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM) 3Health News:Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM) 4Health News:Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM) 5Health News:ECLIPSE data on effects of Otsuka's investigational novel treatment, Tolvaptan 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: